Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Commish Defends Approach To Apple Approvals

Executive Summary

After industry stakeholders raised concerns that Apple may have received preferential treatment when US FDA approved heart-rhythm apps on the Apple Watch Series 4, Commissioner Scott Gottlieb states in a blog post that the agency's approach was in accordance with its standard procedures and reflect the benefit of early interaction with FDA.


Related Content

FDA Explains Why It Approved Apple Watch's De Novo Despite Missing Primary Endpoint
Drug/Software Combo Pathway Coming Soon To US FDA, Gottlieb Says
Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says
FDA's Speedy Apple Watch De Novos Raise Questions For Industry
FDA: Apple De Novo Approvals Signal Innovation To Digital Health Firms
US FDA's Software Pre-Cert Program: Is The Authority On The Books?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts